Article Text

PDF
Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study
  1. Richard James Partington,
  2. Sara Muller,
  3. Toby Helliwell,
  4. Christian D Mallen,
  5. Alyshah Abdul Sultan
  1. Arthritis UK Primary Care Centre, Keele University, Keele, UK
  1. Correspondence to Dr Richard James Partington, Research Institute for Primary Care & Health Science, Keele University, Staffordshire, ST5 5BG, UK; r.partington{at}keele.ac.uk

Abstract

Objective Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in older people. Contemporary estimates of the incidence and prevalence are lacking, and no previous study has assessed treatment patterns at a population level. This study aims to address this.

Methods We extracted anonymised electronic medical records of patients over the age of 40 years from the Clinical Practice Research Datalink in the period 1990–2016. The absolute rate of PMR per 100 000 person-years was calculated and stratified by age, gender and calendar year. Incidence rate ratios were calculated using a Poisson regression model. Among persons with PMR, continuous and total duration of treatment with glucocorticoids (GC) were assessed.

Results 5 364 005 patients were included who contributed 44 million person-years of follow-up. 42 125 people had an incident diagnosis of PMR during the period. The overall incidence rate of PMR was 95.9 per 100 000 (95% CI 94.9 to 96.8). The incidence of PMR was highest in women, older age groups and those living in the South of England. Incidence appears stable over time. The prevalence of PMR in 2015 was 0.85 %. The median (IQR) continuous GC treatment duration was 15.8 (7.9–31.2) months. However, around 25% of patients received more than 4 years in total of GC therapy.

Conclusions The incidence rates of PMR have stabilised. This is the first population-based study to confirm that a significant number of patients with PMR receive prolonged treatment with GC, which can carry significant risks. The early identification of these patients should be a priority in future research.

  • polymyalgia rheumatica
  • corticosteroids
  • treatment
  • epidemiology

Statistics from Altmetric.com

Footnotes

  • Handling editor Josef S Smolen

  • Contributors Study design: RJP, SM, TH, CDM, AAS. Literature search: RJP. Data management: AAS. Data analysis, data interpretation: RJP, AAS. First draft and figures: RJP. Critical revision of drafts: SM, TH, CDM, AAS.

  • Funding RJP is funded by NHS Research and Infrastructure funds. CDM is funded by the NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands, the NIHR School for Primary Care Research, and an NIHR Research Professorship in General Practice, which also supports AAS (NIHR-RP-2014-04-026). TH is funded by an NIHR Clinical Lectureship in General Practice. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funder was not involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

  • Disclaimer This study is based in part on data from the Clinical Practice Research Datalink GOLD database obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. However, the interpretation and conclusions contained in this report are those of the author(s) alone.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval This study was approved by CPRD's inhouse Independent Scientific Advisory Committee (ISAC) for MHRA Database Research (protocol number: 17_203RA).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.